BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30056163)

  • 1. Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.
    Arulananda S; Thapa B; Walkiewicz M; Zapparoli GV; Williams DS; Dobrovic A; John T
    J Thorac Oncol; 2018 Oct; 13(10):1588-1594. PubMed ID: 30056163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.
    Cedrés S; Ponce-Aix S; Iranzo P; Callejo A; Pardo N; Navarro A; Martinez-Marti A; Gómez-Abecia S; Zucchiatti AC; Sansano I; Enguita AB; Miquel JM; Viaplana C; Dienstmann R; Paz-Ares L; Felip E
    Clin Transl Oncol; 2020 Aug; 22(8):1390-1398. PubMed ID: 31916017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch repair status in sporadic colorectal cancer: immunohistochemistry and microsatellite instability analyses.
    Yoon YS; Yu CS; Kim TW; Kim JH; Jang SJ; Cho DH; Roh SA; Kim JC
    J Gastroenterol Hepatol; 2011 Dec; 26(12):1733-9. PubMed ID: 21615788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High homogeneity of MMR deficiency in ovarian cancer.
    Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
    Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms.
    Shia J; Klimstra DS; Nafa K; Offit K; Guillem JG; Markowitz AJ; Gerald WL; Ellis NA
    Am J Surg Pathol; 2005 Jan; 29(1):96-104. PubMed ID: 15613860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer.
    Haron NH; Mohamad Hanif EA; Abdul Manaf MR; Yaakub JA; Harun R; Mohamed R; Mohamed Rose I
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):509-517. PubMed ID: 30803214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
    PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite instability in young patients with mucinous colorectal cancers - characterization using molecular testing, immunohistochemistry, and histological features.
    Mathews NS; Masih D; Mittal R; Perakath B; Sakthi D; Rebekah G; Pai R; Pulimood AB
    Indian J Cancer; 2019; 56(4):309-314. PubMed ID: 31607698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
    Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
    Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
    Nasu M; Emi M; Pastorino S; Tanji M; Powers A; Luk H; Baumann F; Zhang YA; Gazdar A; Kanodia S; Tiirikainen M; Flores E; Gaudino G; Becich MJ; Pass HI; Yang H; Carbone M
    J Thorac Oncol; 2015 Apr; 10(4):565-76. PubMed ID: 25658628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome.
    Lamba AR; Moore AY; Moore T; Rhees J; Arnold MA; Boland CR
    Fam Cancer; 2015 Jun; 14(2):259-64. PubMed ID: 25637498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
    Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma.
    Losi L; Bertolini F; Guaitoli G; Fabbiani L; Banchelli F; Ambrosini-Spaltro A; Botticelli L; Scurani L; Baldessari C; Barbieri F; Cascinu S; Maiorana A
    Int J Oncol; 2019 Nov; 55(5):1157-1164. PubMed ID: 31545419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.